International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner… - The Lancet …, 2016 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
[PDF][PDF] International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in …
D Farge, H Bounameaux, B Brenner… - Lancet …, 2016 - access.archive-ouverte.unige.ch
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner, F Cajfinger… - The Lancet …, 2016 - Elsevier
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
[引用][C] International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in …
D Farge, H Bounameaux, B Brenner, F Cajfinger… - The Lancet …, 2016 - cir.nii.ac.jp
International clinical practice guidelines including guidance for direct oral anticoagulants in the
treatment and prophylaxis of venous thromboembolism in patients with cancer | CiNii Research …
treatment and prophylaxis of venous thromboembolism in patients with cancer | CiNii Research …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner, F Cajfinger… - The Lancet …, 2016 - sonar.ch
English Venous thromboembolism (VTE) is the second leading cause of death in patients
with cancer. These patients are at an increased risk of developing VTE and are more likely …
with cancer. These patients are at an increased risk of developing VTE and are more likely …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner, F Cajfinger… - The Lancet …, 2016 - infona.pl
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner, F Cajfinger… - The Lancet …, 2016 - folia.unifr.ch
English Venous thromboembolism (VTE) is the second leading cause of death in patients
with cancer. These patients are at an increased risk of developing VTE and are more likely …
with cancer. These patients are at an increased risk of developing VTE and are more likely …
[PDF][PDF] International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in …
D Farge, H Bounameaux, B Brenner, F Cajfinger… - Lancet …, 2016 - education.gnicpm.ru
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
[PDF][PDF] International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in …
D FARGE - cancer, 2016 - academia.edu
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner… - Lancet …, 2016 - archive-ouverte.unige.ch
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …